{
    "Clinical Trial ID": "NCT00699491",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Dose Level 1",
        "  25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22",
        "  3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "INTERVENTION 2: ",
        "  Dose Level -1",
        "  20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22",
        "  3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22",
        "  Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically confirmed diagnosis of breast cancer with diagnosis of metastatic or locally recurrent disease (locally recurrent disease should be stage IV e.g. chest wall involvement)",
        "  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 (Karnofsky >= 80%)",
        "  Life expectancy of > 12 weeks",
        "  Capable of understanding investigational nature, potential risks and benefits of the study and able to provide written informed consent",
        "  Negative serum pregnancy test =< 7 days of registration for women of childbearing potential:",
        "  Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study therapy and for 3 months after the last dose of IMC-A12 and CCI-779 (temsirolimus)",
        "  Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",
        "  Nursing women must be willing to discontinue nursing; NOTE: breastfeeding should be discontinued if the mother is treated with CCI-779 and IMC-A12",
        "  Absolute neutrophil count >= 1,500/mcL",
        "  Hemoglobin >= 8.5 g/dL",
        "  Platelets >= 100,000/mcL",
        "  Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)",
        "  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (=< 5 X institutional ULN if liver function test [LFT] elevations due to liver metastases)",
        "  Creatinine =< 1.5 X institutional ULN OR creatinine clearance >= 60 mL/min/1.73^2 for patients with creatinine > institutional ULN",
        "  Fasting serum cholesterol =< 350 mg/dL (9.0 mmol/L)",
        "  Fasting triglycerides =< 400 mg/dL (4.56 mmol/L)",
        "  Albumin >= 3.4 mg/dL",
        "  Fasting or non fasting serum glucose < 120 mg/dL",
        "  Hemoglobin A1c (HbA1c) (for all patients with a history of diabetes mellitus) < 8%",
        "  Phase I only: Any number of prior therapy regimens is allowed",
        "  Phase II only: Measurable disease is required for the Phase II portion of the study; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques (computed tomography [CT], magnetic resonance imaging [MRI], x-ray) or as >= 10 mm with spiral CT scan",
        "  Phase II only: =< two and at least one prior chemotherapy regimens in the setting of metastatic or locally recurrent (stage IV chest wall involvement) disease are required",
        "Exclusion Criteria:",
        "  Phase I patients only: Patients with base line diabetes requiring oral hypoglycemics or insulin",
        "  Phase II patients only: Poorly controlled diabetes mellitus; NOTE: patients with a history of diabetes mellitus on oral hypoglycemics or insulin are allowed to participate, provided that their fasting blood glucose is < 120 mg/dL and that they are on a stable dietary or therapeutic regimen for this condition",
        "  Any of the following:",
        "  Pregnant women",
        "  Nursing women",
        "  Men or women of childbearing potential who are unwilling to employ adequate contraception (hormonal agents are not allowed and oral contraceptives are not acceptable for contraception)",
        "  Receiving hormonal agents used for the treatment of breast cancer with the exception that premenopausal women who have been on a gonadotropin-releasing hormone (GnRH) agonist and subsequently progressed may, at the discretion of the treating physician, continue on the GnRH agonist",
        "  Any of the following prior therapies:",
        "  Systemic anti-cancer therapy =< 3 weeks prior to registration",
        "  Radiation therapy =< 2 weeks prior to registration",
        "  Prior invasive non-breast malignancy, except for adequately treated basal or squamous cell carcinoma of the skin or other cancer from which the patient has been disease free for >= 5 years",
        "  Known hypersensitivity reactions to macrolide antibiotics (such as erythromycin, clarithromycin, and azithromycin); allergic reactions attributed to compounds of similar chemical or biologic composition to IMC-A12, or temsirolimus",
        "  Prior treatment with agents targeting the insulin-like growth factor-I receptor (IGF-IR)/insulin-like growth factors (IGFs) or phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3K)/v-akt murine thymoma viral oncogene homolog 1 (Akt)/mechanistic target of rapamycin (mTOR) pathway",
        "  Receiving any other investigational agents or herbal preparations",
        "  Patients may not be taking oral corticosteroids except for replacement for adrenal insufficiency",
        "  Uncontrolled brain metastases; Note: brain metastases are not permitted on study unless the metastases have been treated by surgery or radiotherapy, and the patient has been neurologically stable and off of steroids for >= 12 weeks",
        "  Known human immunodeficiency virus (HIV)-positive patients who have cluster of differentiation (CD)4 counts below the normal range or who are on anti-retroviral therapy that may interfere with the metabolism of temsirolimus",
        "  Uncontrolled intercurrent illness including, but not limited to:",
        "  Ongoing or active infection",
        "  Symptomatic congestive heart failure",
        "  Unstable angina pectoris",
        "  Uncontrolled symptomatic cardiac arrhythmia",
        "  Psychiatric illness/social situations that would limit compliance with study requirements",
        "  Receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) or any other cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin or St. John's wort"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Recommended Dose Level for Phase II Testing (RPTD) (Phase I)",
        "  The RPTD is defined as the highest dose level at which at most one of 6 patients develops a dose limiting toxicity (DLT) during the first course of treatment and the next highest dose level has 2 or more DLTs. The number of patients in each cohort reporting a DLT is reported.",
        "  Dose-limiting toxicities (DLTs) are defined as any of the following adverse events (AEs) that are related to study agent with an attribution of possible, probably, or definite and fulfilling one of the following criteria:",
        "  Any grade 4 hematologic toxicity",
        "  Hyperglycemia that cannot be stably controlled with diabetic medication",
        "  Any grade 3 or 4 non-hematologic toxicity (except asymptomatic medically manageable laboratory abnormalities such as hyperlipidemia, hypophosphatemia, and hypokalemia)",
        "  Time frame: During first course",
        "Results 1: ",
        "  Arm/Group Title: Dose Level 1",
        "  Arm/Group Description: 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22",
        "  3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: DLTs  2",
        "Results 2: ",
        "  Arm/Group Title: Dose Level -1",
        "  Arm/Group Description: 20 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22",
        "  3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22",
        "  Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 1",
        "  Measure Type: Number",
        "  Unit of Measure: DLTs  1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/3 (0.00%)",
        "  Hemoglobin decreased 0/3 (0.00%)",
        "  Mucositis oral 0/3 (0.00%)",
        "  Nausea 0/3 (0.00%)",
        "  Vomiting 0/3 (0.00%)",
        "  Death 0/3 (0.00%)",
        "  Edema limbs 0/3 (0.00%)",
        "  Fatigue 0/3 (0.00%)",
        "  Pain 0/3 (0.00%)",
        "  Skin infection 0/3 (0.00%)",
        "  Alanine aminotransferase increased 0/3 (0.00%)",
        "  Alkaline phosphatase increased 0/3 (0.00%)",
        "  Creatinine increased 0/3 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/2 (50.00%)",
        "  Hemoglobin decreased 0/2 (0.00%)",
        "  Mucositis oral 1/2 (50.00%)",
        "  Nausea 0/2 (0.00%)",
        "  Vomiting 0/2 (0.00%)",
        "  Death 0/2 (0.00%)",
        "  Edema limbs 0/2 (0.00%)",
        "  Fatigue 1/2 (50.00%)",
        "  Pain 1/2 (50.00%)",
        "  Skin infection 0/2 (0.00%)",
        "  Alanine aminotransferase increased 0/2 (0.00%)",
        "  Alkaline phosphatase increased 0/2 (0.00%)",
        "  Creatinine increased 1/2 (50.00%)"
    ]
}